mk 0663 has been researched along with rofecoxib in 37 studies
| Studies (mk 0663) | Trials (mk 0663) | Recent Studies (post-2010) (mk 0663) | Studies (rofecoxib) | Trials (rofecoxib) | Recent Studies (post-2010) (rofecoxib) |
|---|---|---|---|---|---|
| 549 | 173 | 265 | 1,914 | 307 | 163 |
| Protein | Taxonomy | mk 0663 (IC50) | rofecoxib (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | 0.43 | |
| Cytochrome c oxidase subunit 2 | Homo sapiens (human) | 1.51 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.5 | |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 0.5 | |
| Calpain-2 catalytic subunit | Homo sapiens (human) | 0.02 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 1.8 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.3602 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.76 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.486 | |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.036 | |
| Sodium-dependent serotonin transporter | Macaca mulatta (Rhesus monkey) | 0.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (64.86) | 29.6817 |
| 2010's | 11 (29.73) | 24.3611 |
| 2020's | 2 (5.41) | 2.80 |
| Authors | Studies |
|---|---|
| Byun, Y; Choi, JK; Choi, YH; Chung, S; Jeong, YS; Kim, JK; Kim, JY; Koh, HJ; Lee, KW; Lim, KM; Moh, JH; Noh, MS; Oh, YI; Park, YH; Shin, SS | 1 |
| Amat, M; Beleta, J; Cárdenas, A; Caturla, F; Crespo, MI; Godessart, N; Jiménez, JM; Ryder, H; Soca, L | 1 |
| Beswick, P; Bingham, S; Bountra, C; Brown, T; Browning, K; Campbell, I; Chessell, I; Clayton, N; Collins, S; Corfield, J; Guntrip, S; Haslam, C; Lambeth, P; Lucas, F; Mathews, N; Murkit, G; Naylor, A; Pegg, N; Pickup, E; Player, H; Price, H; Stevens, A; Stratton, S; Wiseman, J | 1 |
| Augustyniak, ME; Earl, RA; Garvey, DS; Janero, DR; Khanapure, SP; Letts, LG; Martino, AM; Murty, MG; Schwalb, DJ; Shumway, MJ; Trocha, AM; Young, DV; Zemtseva, IS | 1 |
| Amat, M; Caturla, F; Córdoba, M; Reinoso, RF; Warrellow, G | 1 |
| Amat, M; Calaf, E; Caturla, F; Reinoso, RF; Warrellow, G | 1 |
| Beswick, PJ; Bingham, S; Bountra, C; Carter, MC; Chambers, LJ; Chessell, IP; Clayton, NM; Collins, SD; Corfield, JA; Gleave, RJ; Green, RH; Hartley, CD; Kleanthous, S; Lambeth, PF; Lucas, FS; Mathews, N; Naylor, A; Page, LW; Payne, JJ; Pegg, NA; Price, HS; Skidmore, J; Stevens, AJ; Stocker, R; Stratton, SC; Stuart, AJ; Swarbrick, ME; Wiseman, JO | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Brideau, C; Ducharme, Y; Dufresne, L; Friesen, RW; Guiral, S; Juteau, H; Mancini, J; Poirier, H; Riendeau, D; Salem, M; Wu, TY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Ramajayam, R | 1 |
| Ouellet, M; Percival, MD; Riendeau, D | 1 |
| Hardy, KJ; McMurray, RW | 1 |
| Capone, ML; Patrignani, P; Ricciotti, E; Sciulli, MG; Tacconelli, S | 1 |
| Chan, VS | 1 |
| Benoit, V; de Leval, X; Dogné, JM; Frederich, M; Julémont, F; Pirotte, B | 1 |
| Liu, W; Loo, CC; Ren, HZ; Tan, HM; Ye, TH | 1 |
| Hochberg, MC | 1 |
| Meena, S; Nageswara Rao, R; Raghuram Rao, A | 1 |
| Curtis, SP; Eyster, ME; Giallella, KM; Melian, A; Mukhopadhyay, S; Reicin, AS; Shingo, S; Tsoukas, C | 1 |
| Andersohn, F; Garbe, E; Schade, R; Suissa, S | 1 |
| Boshier, A; Friedmann, P; Layton, D; Marshall, V; Shakir, SA | 1 |
| Broich, K; Heim, HK | 1 |
| Tabrizchi, R | 1 |
| Lindsley, CW | 1 |
| Ashcroft, DM; Chen, LC | 1 |
| Avorn, J | 1 |
| Mielke, F; Schweigert, M | 1 |
| Andreesen, R; Berand, A; Reichle, A; Rogenhofer, S; Vogelhuber, M; Walter, B; Wieland, WF | 1 |
| Elliott, WJ | 1 |
| Honjo, H; Iwamoto, K; Uwai, Y | 1 |
| Hu, RW; Li, HY; Li, JS; Miao, XP; Ouyang, Q; Zhang, Y | 1 |
| Dulski, M; Grzybowska, K; Jurkiewicz, K; Knapik, J; Paluch, M; Rams-Baron, M; Ratuszna, A; Sawicki, W; Smolka, W; Wojnarowska, Z | 1 |
| Hansen, SH; Skonberg, C; Syed, M | 1 |
| Arfè, A; Castellsague, J; Garbe, E; Herings, R; Kollhorst, B; Lucchi, S; Masclee, GMC; Perez-Gutthann, S; Romio, S; Schade, R; Schink, T; Schuemie, MJ; Scotti, L; Straatman, H; Sturkenboom, MCJM; Valkhoff, VE; Varas-Lorenzo, C; Villa, M | 1 |
| Kleszcz, R; Krajka-Kuźniak, V; Kruhlenia, N; Majchrzak-Celińska, A; Misiorek, JO; Przybyl, L; Rolle, K | 1 |
| Hjemdahl, P; Stiller, CO | 1 |
10 review(s) available for mk 0663 and rofecoxib
| Article | Year |
|---|---|
Medicinal chemistry of vicinal diaryl scaffold: A mini review.
Topics: Carbonic Anhydrase IV; Chemistry, Pharmaceutical; Cyclooxygenase 2 Inhibitors; Drug Discovery; Humans; Hydrocarbons, Aromatic; Structure-Activity Relationship | 2019 |
Cox-2 inhibitors: today and tomorrow.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Etoricoxib; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Research; Sulfonamides; Sulfones | 2002 |
A mechanistic perspective on the specificity and extent of COX-2 inhibition in pregnancy.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Female; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Pregnancy; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2004 |
First and second generations of COX-2 selective inhibitors.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2004 |
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Membrane Proteins; Organic Chemicals; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Rheumatology; Sulfonamides; Sulfones; Treatment Outcome | 2005 |
An overview of the recent developments in analytical methodologies for determination of COX-2 inhibitors in bulk drugs, pharmaceuticals and biological matrices.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Industry; Etodolac; Etoricoxib; Lactones; Models, Chemical; Pyrazoles; Pyridines; Spectrophotometry; Sulfonamides; Sulfones; Ultraviolet Rays | 2005 |
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones | 2007 |
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Hypertension; Isoxazoles; Lactones; Pyrazoles; Pyridines; Risk; Risk Factors; Sulfonamides; Sulfones | 2010 |
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Crohn Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Sulfonamides; Sulfones | 2014 |
Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Fibrinolytic Agents; Humans; Ibuprofen; Lactones; Naproxen; Prostaglandins; Prostaglandins I; Sulfones; Thromboxanes | 2022 |
3 trial(s) available for mk 0663 and rofecoxib
| Article | Year |
|---|---|
[Comparison of preemptive analgesia efficacy between etoricoxib and rofecoxib in ambulatory gynecological surgery].
Topics: Abortion, Induced; Acetaminophen; Adolescent; Adult; Ambulatory Surgical Procedures; Analgesics, Non-Narcotic; Analgesics, Opioid; Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Female; Fentanyl; Humans; Lactones; Pain Measurement; Pain, Postoperative; Preoperative Care; Pyridines; Sulfones | 2004 |
Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy.
Topics: Adolescent; Adult; Aged; Child; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Etoricoxib; Female; Headache; Hemarthrosis; Hemophilia A; Humans; Lactones; Male; Membrane Proteins; Middle Aged; Pyridines; Respiratory Tract Infections; Sulfones; Treatment Outcome | 2006 |
Modular therapy approach in metastatic castration-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Capecitabine; Deoxycytidine; Dexamethasone; Disease Progression; Drug Therapy, Combination; Etoricoxib; Fluorouracil; Humans; Kaplan-Meier Estimate; Lactones; Male; Orchiectomy; Pioglitazone; Prostatic Neoplasms; Pyridines; Sulfones; Thiazolidinediones; Treatment Outcome | 2010 |
24 other study(ies) available for mk 0663 and rofecoxib
| Article | Year |
|---|---|
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
Topics: Adult; Animals; Arthritis, Experimental; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Edema; Furans; Humans; In Vitro Techniques; Isoenzymes; Macrophages, Peritoneal; Male; Membrane Proteins; Mice; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Sprague-Dawley; Stomach Ulcer; Structure-Activity Relationship | 2004 |
Synthesis and biological evaluation of 2-phenylpyran-4-ones: a new class of orally active cyclooxygenase-2 inhibitors.
Topics: Administration, Oral; Animals; Arthritis, Experimental; Blood Proteins; Cyclooxygenase 2; Humans; Hyperalgesia; Isoenzymes; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Protein Binding; Pyrans; Rats; Rats, Wistar; Structure-Activity Relationship | 2004 |
Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.
Topics: Administration, Oral; Animals; Arthritis, Experimental; Biological Availability; Brain; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Freund's Adjuvant; Humans; Infusions, Intravenous; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridazines; Rats; Structure-Activity Relationship | 2004 |
3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation.
Topics: Administration, Oral; Animals; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Inflammation; Male; Prostaglandin-Endoperoxide Synthases; Pyridines; Rats; Rats, Sprague-Dawley; Sulfones | 2005 |
Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx and Arcoxia.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Isomerism; Lactones; Male; Molecular Structure; Prodrugs; Pyridines; Rats; Rats, Wistar; Safrole; Solubility; Sulfones; Temperature; Thermodynamics | 2006 |
Racemic and chiral sulfoxides as potential prodrugs of 4-pyrone COX-2 inhibitors.
Topics: Animals; Crystallography, X-Ray; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Humans; Male; Models, Molecular; Molecular Structure; Prodrugs; Rats; Rats, Wistar; Stereoisomerism; Structure-Activity Relationship; Sulfones; Sulfoxides | 2006 |
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.
Topics: Amines; Animals; Brain; Chemistry, Pharmaceutical; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Drug Design; Ethers; Humans; Inflammation; Inhibitory Concentration 50; Mice; Molecular Structure; Neurodegenerative Diseases; Pyrimidines; Rats; Sulfones | 2009 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Biarylimidazoles as inhibitors of microsomal prostaglandin E2 synthase-1.
Topics: Animals; Anti-Inflammatory Agents; Cell Line; Dinoprostone; High-Throughput Screening Assays; Imidazoles; Intramolecular Oxidoreductases; Mice; Microsomes; Prostaglandin-E Synthases | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.
Topics: Acetylation; Animals; Aspirin; Blood Platelets; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Ibuprofen; In Vitro Techniques; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sheep; Sulfonamides; Sulfones | 2001 |
The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity.
Topics: Adult; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Female; Humans; In Vitro Techniques; Isoenzymes; Isoxazoles; Italy; Lactones; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyridines; Sulfonamides; Sulfones | 2002 |
Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Brain Ischemia; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; Dose-Response Relationship, Drug; Etoricoxib; Female; Humans; Lactones; Logistic Models; Male; Medical Records Systems, Computerized; Middle Aged; Odds Ratio; Pyrazoles; Pyridines; Sulfonamides; Sulfones; United Kingdom | 2006 |
Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Prescriptions; England; Etoricoxib; Female; Humans; Incidence; Lactones; Male; Middle Aged; Pyrazoles; Pyridines; Research Design; Retrospective Studies; Skin; Stevens-Johnson Syndrome; Sulfonamides; Sulfones; Surveys and Questionnaires | 2006 |
Selective COX-2 inhibitors and risk of thromboembolic events - regulatory aspects.
Topics: Adverse Drug Reaction Reporting Systems; Animals; Arthritis; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Approval; Drug Evaluation, Preclinical; Etoricoxib; European Union; Humans; Lactones; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides; Sulfones; Thromboembolism | 2006 |
Coxibs: can this class of drugs survive?
Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Evidence-Based Medicine; Half-Life; Humans; Isoxazoles; Lactones; Patient Selection; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2005 |
Emerging from the shadow of Vioxx.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Drug Approval; Etoricoxib; Humans; Lactones; Pyridines; Sulfones | 2007 |
Keeping science on top in drug evaluation.
Topics: Advisory Committees; Cardiovascular Diseases; Conflict of Interest; Cyclooxygenase Inhibitors; Dexfenfluramine; Drug Approval; Drug Evaluation; Drug Industry; Etoricoxib; Humans; Hypoglycemic Agents; Lactones; Pyridines; Risk; Rosiglitazone; Sulfones; Thiazolidinediones; United States; United States Food and Drug Administration | 2007 |
Safe adalimumab therapy for rheumatoid arthritis in a patient with pre-existing multiple myeloma.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Etoricoxib; Humans; Lactones; Male; Methotrexate; Middle Aged; Multiple Myeloma; Pyridines; Retrospective Studies; Severity of Illness Index; Sulfones | 2008 |
Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3.
Topics: Animals; Binding, Competitive; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Estrone; Etoricoxib; Humans; Inhibitory Concentration 50; Isoxazoles; Kinetics; Lactones; Methotrexate; Oocytes; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Pyrazoles; Pyridines; RNA, Complementary; Sulfonamides; Sulfones; Xenopus laevis | 2010 |
Toward a Better Understanding of the Physical Stability of Amorphous Anti-Inflammatory Agents: The Roles of Molecular Mobility and Molecular Interaction Patterns.
Topics: Anti-Inflammatory Agents; Celecoxib; Crystallization; Dielectric Spectroscopy; Drug Stability; Etoricoxib; Lactones; Pyridines; Sulfones | 2015 |
Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria.
Topics: Adenosine Triphosphate; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Isoxazoles; Lactones; Male; Mitochondria, Liver; Oxidative Phosphorylation; Pyridines; Rats, Sprague-Dawley; Sulfonamides; Sulfones | 2016 |
Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Diclofenac; Etoricoxib; Female; Humans; Indomethacin; Ketorolac; Lactones; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Risk Factors; Sulfones | 2018 |
COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Etoricoxib; Female; Glioblastoma; Humans; Isoxazoles; Lactones; Male; Methylation; Middle Aged; Neoplasm Proteins; Pyrazoles; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Sulfones; Temozolomide; Tumor Suppressor Proteins; Wnt Signaling Pathway | 2021 |